Adversarial re-check confirms the sources are real, live, and support the outcome. On the 'puts profits above people' prong, Trump personally LED an aggressive, high-profile campaign against pharma pricing: he signed the Most-Favored-Nation prescription-drug executive order (May 12, 2025), sent demand letters to 17 named pharma CEOs (published on Truth Social), struck 16 price-lowering deals with major manufacturers (Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, Merck, Novartis and others), and launched TrumpRx.gov for direct discounted purchases. That is unambiguously 'actively led/drove the effort,' well beyond a single supporting vote, so CHAMPIONED fits. Fairness test: a Democratic president with this identical record (driving drug-pricing EOs, CEO demand letters, and 16 negotiated deals) would be credited as championing, so the label is not partisan leniency. Two corrections to the prior rationale: (1) the prior rating leaned on the DOJ FY2025 record False Claims Act recoveries ($6.8B, largest from pharma) as evidence of championing the FRAUD prong, but ~78% of those recoveries were whistleblower/qui-tam-driven from cases filed years earlier — routine DOJ enforcement, not personally championed — so that prong is weak; however, the pricing prong alone independently sustains CHAMPIONED. (2) The deals are genuinely contested (3-year tariff grace periods, secret undisclosed terms, no proven consumer savings yet; Wyden/Senate Democrats call it a 'Big Pharma Giveaway' and 'fakery'), which is precisely why FULL is wrong and CHAMPIONED (not FULL) is the correctly calibrated label. Confidence trimmed slightly from 0.72 to 0.70 to reflect the weak fraud-prong attribution and unproven consumer outcomes, but the outcome stands.